Results 241 to 250 of about 1,494,935 (289)
Some of the next articles are maybe not open access.

Hypopigmentation in Dogs Treated with an Inhibitor of Platelet Aggregation

Toxicologic Pathology, 1989
Hypopigmentation was the principal manifestation of systemic toxicity when the experimental platelet aggregation inhibitor, PD-89454, was orally administered to Beagle dogs for 28 days. Pigmentation changes were present in skin of nose, lips and eyelids and mucosa of hard palate.
K M, Walsh, A W, Gough
openaire   +2 more sources

Inhibitors of “spontaneous” platelet aggregation in whole blood

Atherosclerosis, 1985
In vitro 'spontaneous' platelet aggregation has been studied in whole blood. The spectrum of activity of materials known to influence platelet aggregation in platelet-rich plasma proved different in whole blood. Thus dipyridamole and one of its analogues SH1242 had a striking effect in whole blood whilst aspirin, chlorpromazine and K3920 had little or ...
M J, Harrison   +3 more
openaire   +2 more sources

Lebetin Peptides: Potent Platelet Aggregation Inhibitors

Pathophysiology of Haemostasis and Thrombosis, 2001
Lebetins from <i>Macrovipera lebetina</i> snake venom constitute a new class of inhibitors of platelet aggregation. There are two groups of peptides: lebetin 1 (L1; 11- to 13-mer) and lebetin 2 (L2; 37- to 38-mer). The short lebetins are identical to the N-terminal segments of the longer ones.
N, Marrakchi   +6 more
openaire   +2 more sources

Bleeding in a Patient Receiving Platelet Aggregation Inhibitors

Anesthesia & Analgesia, 2001
We describe a patient who experienced intraoperative bleeding after being treated with platelet receptor glycoprotein IIb/IIIa antagonist eptifibatide. We used Sonoclot and Thrombelastograph to monitor antiplatelet effects of eptifibatide.
J H, Waters   +3 more
openaire   +2 more sources

Platelet turnover in metastatic cancer and the effect of platelet aggregation inhibitors

Zeitschrift f�r Krebsforschung und Klinische Onkologie, 1976
Patients with metastatic cancer have a permanent shortening of platelet survival and increased platelet consumption. Acetylsalicylic acid or dipyridamole in doses known to inhibit platelet aggregation, had no effect on platelet consumption.
openaire   +2 more sources

The Clinical Landscape of HDAC Inhibitors

Medical Epigenetics, 2021
Arasu Ganesan
exaly  

Therapeutics and DNA Methylation Inhibitors

Medical Epigenetics, 2021
Shyamala C Navada
exaly  

Inhibitors of Platelet Aggregation

1986
K. M. Lakin, V. A. Makarov
openaire   +1 more source

Home - About - Disclaimer - Privacy